Skip to main content

Clinical trials vital to Alzheimer's research

Clinical drug trials help future AD sufferers.
Clinical drug trials help future AD sufferers.
Windows Photo Gallery

Presently there is no known cure for the 5.3 million Americans living with Alzheimer’s disease (AD). This makes research into this devastating illness even more important. Clinical drug trials for potential AD medications are one way to help researchers find safe and effective treatments for sufferers.

If someone you know recently has been diagnosed with Alzheimer’s they may be eligible to participate in studies exploring new investigational drugs for the disease.

Investigational Clinical Amyloid Research in Alzheimer’s (ICARA) and Empire Neurology, P.C. are now recruiting participants to help determine if the drug bapineuzumab (bapi) —aimed at treating mild to moderate AD—can aid in slowing the disease’s progression.

Generally study-related physical examinations and laboratory services are provided to participants free-of-charge. Individuals are monitored by a physician and registered nurse or study coordinator and are randomly selected to receive the investigational drug or a placebo.

Anyone between the ages of 50 and 88 who has received a probable Alzheimer’s diagnosis is eligible to participate. Studies will be conducted in the Albany area.

For more information contact Empire Neurology, P.C. at (518) 785-1000 or visit www.ICARAstudy.com. The Alzheimer’s Association also posts information on other AD-related clinical trials.
 

Comments